Importer of Controlled Substances Application: Usona Institute, 31537-31538 [2021-12353]
Download as PDF
<![CDATA[
31537
Federal Register / Vol. 86, No. 112 / Monday, June 14, 2021 / Notices
lotter on DSK11XQN23PROD with NOTICES1
that such articles should not be excluded
from entry.
19 U.S.C. 1337(d)(1). A similar
provision applies to cease and desist
orders. 19 U.S.C. 1337(f)(1).
The Commission is soliciting
submissions on public interest issues
raised by the recommended relief
should the Commission find a violation,
specifically: A limited exclusion order
directed to certain laparoscopic surgical
staplers, reload cartridges, and
components thereof imported, sold for
importation, and/or sold after
importation by respondents Intuitive
Surgical Inc.; Intuitive Surgical
Operations, Inc.; Intuitive Surgical
Holdings, LLC; and Intuitive Surgical S.
De R.L. De C.V.; and cease and desist
orders directed to the same. Parties are
to file public interest submissions
pursuant to 19 CFR 210.50(a)(4).
The Commission is interested in
further development of the record on
the public interest in this investigation.
Accordingly, members of the public are
invited to file submissions of no more
than five (5) pages, inclusive of
attachments, concerning the public
interest in light of the ALJ’s
Recommended Determination on
Remedy and Bonding issued in this
investigation on June 8, 2021.
Comments should address whether
issuance of the recommended remedial
orders in this investigation, should the
Commission find a violation, would
affect the public health and welfare in
the United States, competitive
conditions in the United States
economy, the production of like or
directly competitive articles in the
United States, or United States
consumers.
In particular, the Commission is
interested in comments that:
(i) Explain how the articles
potentially subject to the recommended
remedial orders are used in the United
States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the recommended orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or thirdparty suppliers have the capacity to
replace the volume of articles
potentially subject to the recommended
orders within a commercially
reasonable time; and
(v) explain how the recommended
orders would impact consumers in the
United States.
VerDate Sep<11>2014
17:26 Jun 11, 2021
Jkt 253001
Written submissions must be filed no
later than by close of business on July
8, 2021.
Persons filing written submissions
must file the original document
electronically on or before the deadlines
stated above. The Commission’s paper
filing requirements in 19 CFR 210.4(f)
are currently waived. 85 FR 15798
(March 19, 2020). Submissions should
refer to the investigation number (‘‘Inv.
No. 337–TA–1167’’) in a prominent
place on the cover page and/or the first
page. See Handbook for Electronic
Filing Procedures, https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf.) Persons with
questions regarding filing should
contact the Secretary (202–205–2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel, solely for cybersecurity
purposes. All contract personnel will
sign appropriate nondisclosure
agreements. All nonconfidential written
submissions will be available for public
inspection on EDIS.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and in Part 210 of the Commission’s
Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: June 9, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–12409 Filed 6–11–21; 8:45 am]
BILLING CODE 7020–02–P
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–850]
Importer of Controlled Substances
Application: Usona Institute
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Usona Institute has applied to
be registered as an importer of basic
class(es) of controlled substance(s).
Refer to Supplemental Information
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 14, 2021. Such persons
may also file a written request for a
hearing on the application on or before
July 14, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 10, 2021, Usona
Institute, 2780 Woods Hollow Road,
Room 2412, Fitchburg, Wisconsin
53711–5370, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
DATES:
Controlled substance
5-Methoxy-N-Ndimethyltryptamine.
Dimethyltryptamine ...
Psilocybin .................
Psilocyn ....................
Drug
code
Schedule
7431
I
7435
7437
7438
I
I
I
The institute plans to import the
listed controlled substances to be used
for research and analytical purposes.
The materials will not be used for
clinical trials or bulk manufacture. No
E:\FR\FM\14JNN1.SGM
14JNN1
31538
Federal Register / Vol. 86, No. 112 / Monday, June 14, 2021 / Notices
other activity for these drug codes is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–12353 Filed 6–11–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–849]
Controlled substance
Drug
code
Schedule
Marihuana Extract ....
7350
I
The company plans to import the
above controlled substance as finished
dosage forms for clinical trials. No other
activity for this drug code is authorized
for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
William T. McDermott,
Assistant Administrator.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
BILLING CODE P
AGENCY:
Fisher Clinical Services, Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 14, 2021. Such persons
may also file a written request for a
hearing on the application on or before
July 14, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 17, 2021, Fisher
Clinical Services, Inc., 700A–C Nestle
Way, Breinigsville, Pennsylvania
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
18031–1522, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
VerDate Sep<11>2014
17:26 Jun 11, 2021
Jkt 253001
[FR Doc. 2021–12350 Filed 6–11–21; 8:45 am]
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[Notice: (21–037)]
NASA Astrophysics Advisory
Committee; Meeting
National Aeronautics and
Space Administration.
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, Public
Law 92–463, as amended, the National
Aeronautics and Space Administration
(NASA) announces a meeting of the
Astrophysics Advisory Committee. This
Committee reports to the Director,
Astrophysics Division, Science Mission
Directorate, NASA Headquarters. The
meeting will be held for the purpose of
soliciting, from the scientific
community and other persons, scientific
and technical information relevant to
program planning.
DATES: Tuesday, June 29, 2021, 11:00
a.m.–5:00 p.m., Eastern Time; and
Wednesday, June 30, 2021, 11:00 a.m.–
5:00 p.m., Eastern Time.
FOR FURTHER INFORMATION CONTACT: Ms.
KarShelia Henderson, Science Mission
Directorate, NASA Headquarters,
Washington, DC 20546, (202) 358–2355,
or khenderson@nasa.gov.
SUPPLEMENTARY INFORMATION: The
meeting will be virtual and available to
the public by WebEx and dial-in
teleconference. On Tuesday, June 29,
the event address for attendees is:
SUMMARY:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
https://nasaenterprise.webex.com/
nasaenterprise/j.php?MTID=
m19281c9d7b875a40a767c1af1f5fd5d4,
the meeting number is 199 024 6323,
and meeting password is 2bkHspPS@65.
On Wednesday, June 30, the event
address for attendees is: https://
nasaenterprise.webex.com/
nasaenterprise/j.php?MTID=
mc4d6d874b2e677b1e6460c8fb1b8df0a,
the meeting number is 199 642 8616,
and meeting password is XZgYwCr2@
65. To join by telephone, the numbers
are: 1–929–251–9612 or 1–415–527–
5035, for each day.
The agenda for the meeting includes
the following topics:
—Astrophysics Division Update
—Updates on Specific Astrophysics
Missions
—Reports from the Program Analysis
Groups
—Report on Science Activation Program
The agenda will be posted on the
Astrophysics Advisory Committee web
page: https://science.nasa.gov/
researchers/nac/science-advisorycommittees/apac.
The public may submit and upvote
comments/questions ahead of the
meeting through the website https://
arc.cnf.io/sessions/qgpt/#!/dashboard
that will be opened for input on June 14,
2021.
It is imperative that the meeting be
held on this date to accommodate the
scheduling priorities of the key
participants.
Patricia Rausch,
Advisory Committee Management Officer,
National Aeronautics and Space
Administration.
[FR Doc. 2021–12446 Filed 6–11–21; 8:45 am]
BILLING CODE 7510–13–P
NATIONAL SCIENCE FOUNDATION
Sunshine Act Meeting
The National Science Board’s ad hoc
Committee on Nominating NSB Class of
2022–2028 (NOMS), hereby gives notice
of the scheduling of a teleconference for
the transaction of National Science
Board business, as follows:
TIME AND DATE: Thursday, June 17, 2021,
from 11:30 a.m.–12:00 p.m. EDT.
PLACE: This meeting will be held by
teleconference through the National
Science Foundation, 2415 Eisenhower
Avenue, Alexandria, VA 22314.
STATUS: Closed.
MATTERS TO BE CONSIDERED: The agenda
of the teleconference is: To review the
master list of NSB Nominees, discuss
review and rating guidance, and receive
reviewing assignments.
E:\FR\FM\14JNN1.SGM
14JNN1
]]>Agencies
[Federal Register Volume 86, Number 112 (Monday, June 14, 2021)]
[Notices]
[Pages 31537-31538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12353]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-850]
Importer of Controlled Substances Application: Usona Institute
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Usona Institute has applied to be registered as an importer of
basic class(es) of controlled substance(s). Refer to Supplemental
Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before July 14, 2021.
Such persons may also file a written request for a hearing on the
application on or before July 14, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 10, 2021, Usona Institute, 2780 Woods Hollow
Road, Room 2412, Fitchburg, Wisconsin 53711-5370, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
5-Methoxy-N-N-dimethyltryptamine...... 7431 I
Dimethyltryptamine.................... 7435 I
Psilocybin............................ 7437 I
Psilocyn.............................. 7438 I
------------------------------------------------------------------------
The institute plans to import the listed controlled substances to
be used for research and analytical purposes. The materials will not be
used for clinical trials or bulk manufacture. No
[[Page 31538]]
other activity for these drug codes is authorized for this
registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-12353 Filed 6-11-21; 8:45 am]
BILLING CODE P
